Genfit Stock (NASDAQ:GNFT)
Previous Close
$4.48
52W Range
$3.08 - $6.42
50D Avg
$5.31
200D Avg
$4.33
Market Cap
$214.90M
Avg Vol (3M)
$13.82K
Beta
1.12
Div Yield
-
GNFT Company Profile
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
GNFT Performance
Peer Comparison
Ticker | Company |
---|---|
CYT | Cyteir Therapeutics, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
ACRV | Acrivon Therapeutics, Inc. Common Stock |
FENC | Fennec Pharmaceuticals Inc. |
CSBR | Champions Oncology, Inc. |
ERYP | PHAXIAM Therapeutics S.A. |
JANX | Janux Therapeutics, Inc. |
ANTX | AN2 Therapeutics, Inc. |
KROS | Keros Therapeutics, Inc. |
HCWB | HCW Biologics Inc. |
HRMY | Harmony Biosciences Holdings, Inc. |
MNOV | MediciNova, Inc. |
RZLT | Rezolute, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
ADAG | Adagene Inc. |
MOLN | Molecular Partners AG |
ELYM | Eliem Therapeutics, Inc. |